Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy
Andrei A. Deviatkin,
Yulia A. Vakulenko,
Ludmila V. Akhmadishina,
Vadim V. Tarasov,
Marina I. Beloukhova,
Andrey A. Zamyatnin Jr.,
Alexander N. Lukashev
Affiliations
Andrei A. Deviatkin
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia
Yulia A. Vakulenko
Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia
Ludmila V. Akhmadishina
Martsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia
Vadim V. Tarasov
Department of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University, 119991 Moscow, Russia
Marina I. Beloukhova
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia
Andrey A. Zamyatnin Jr.
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia
Alexander N. Lukashev
Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia
Rheumatoid arthritis (RA) is a systemic inflammatory joint disease affecting about 1% of the population worldwide. Current treatment approaches do not ensure a cure for every patient. Moreover, classical regimens are based on nontargeted systemic immune suppression and have significant side effects. Biological treatment has advanced considerably but efficacy and specificity issues remain. Gene therapy is one of the potential future directions for RA therapy, which is rapidly developing. Several gene therapy trials done so far have been of moderate success, but experimental and genetics studies have yielded novel targets. As a result, the arsenal of gene therapy tools keeps growing. Currently, both viral and nonviral delivery systems are used for RA therapy. Herein, we review recent approaches for RA gene therapy.
